Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine-Reference-Cited by-同舟云学术

Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine

Published:2020-03-24 Issue:5 Volume:189 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

May Annette M.¹²^ORCID,Stomper Julia²³^ORCID,Joeckel Tina E.²³,Bronsert Peter¹²⁴,Wijermans Pierre W.⁵,Werner Martin¹²⁴⁶,Lübbert Michael²³⁶

Affiliation:

1. Institute for Surgical Pathology Medical Center – University of Freiburg Freiburg Germany

2. Faculty of Medicine University of Freiburg Freiburg Germany

3. Division of Hematology, Oncology and Stem Cell Transplantation Department of Medicine University of Freiburg Medical Center Freiburg Germany

4. Tumorbank, Comprehensive Cancer Center Freiburg Medical Center – University of Freiburg Faculty of Medicine University of Freiburg Freiburg Germany

5. HagaZiekenhuis The Hague The Netherlands

6. German Consortium for Translational Cancer Research Freiburg Germany

Funder

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16615

Reference15 articles.

1. Current therapy of myelodysplastic syndromes

2. Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

3. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group

4. Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients

5. The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Absence of early platelet increment in healthy mice during decitabine treatment;Scientific Reports;2022-12-23